CytRx Corporation (CYTR) : The consensus on CytRx Corporation (CYTR) based on 3 analyst recommendation on the company stock is 1.67, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 2 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
CytRx Corporation (CYTR) : 3 Wall Street analysts covering CytRx Corporation (CYTR) believe that the average level the stock could reach for the short term is $4.58. The maximum price target given is $10 and the minimum target for short term is around $1, hence the standard deviation is calculated at $4.82.
For the current week, the company shares have a recommendation consensus of Buy.
CytRx Corporation (NASDAQ:CYTR): stock was range-bound between the intraday low of $0.5756 and the intraday high of $0.6 after having opened at $0.6 on Wednesdays session. The stock finally closed in the red at $0.6, a loss of -0.09%. The stock remained in the red for the whole trading day. The total traded volume was 921,913 shares. The stock failed to cross $0.6 in Wednesdays trading. The stocks closing price on Thursday was $0.578.
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The company is focused on the clinical development of aldoxorubicin, its modified version of a chemotherapeutic agent. Aldoxorubicin is a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is concentrated at the site of tumors. It consists of (6-Maleimidocaproyl) hydrazine, an acid-sensitive molecule that is conjugated to doxorubicin. Its laboratory in Freiburg, Germany is conducting discovery and translational research to create drug candidates that utilize linker technologies that couple chemotherapeutic agents and proteins either inside the body or externally, and then concentrate drug in tumors.